| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5221763 | SUCAMPO PHARMA LLC | Prostaglandins of the F series |
Jul, 2012
(11 years ago) | |
| US6770675 | SUCAMPO PHARMA LLC | Compositions and methods for reducing ocular hypertension |
Nov, 2018
(5 years ago) | |
| US6458836 | SUCAMPO PHARMA LLC | Treatment of ocular hypertension and glaucoma |
Jul, 2021
(2 years ago) | |
Rescula is owned by Sucampo Pharma Llc.
Rescula contains Unoprostone Isopropyl.
Rescula has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Rescula are:
- US5221763
- US6770675
- US6458836
Rescula was authorised for market use on 03 August, 2000.
Rescula is available in solution/drops;ophthalmic dosage forms.
Rescula can be used as method of treating ocular hypertension, method of reducing ocular hypertension.
The generics of Rescula are possible to be released after 09 July, 2021.
Drugs and Companies using UNOPROSTONE ISOPROPYL ingredient
Market Authorisation Date: 03 August, 2000
Treatment: Method of reducing ocular hypertension; Method of treating ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
RESCULA family patents
